http://archinte.jamanetwork.com/ en-us Mon, 28 Jan 2013 00:00:00 GMT Mon, 04 Feb 2013 15:47:23 GMT Silverchair editor@archinte.jamanetwork.com webmaster@archinte.jamanetwork.com http://archinte.jamanetwork.com/article.aspx?articleID=1483960 Mon, 28 Jan 2013 00:00:00 GMT Grann V, Ashby-Thompson M. <span class="paragraphSection">Genetic history of BRCA1/2 mutations identifies women who are at high risk for breast and ovarian cancer and who may benefit from more intensive screening and/or risk-reducing surgeries. BRCA1/2 mutations account for 5% to 10% of all breast cancers in the United States and approximately 10% of ovarian cancers. Women with mutations may develop cancers at an early age, leading to psychological distress and loss of both quality and quantity of life. The cost of preventive screening and treatment for BRCA1/2 mutations accounts for approximately $800 million of the more than $8 billion spent each year for treatment of breast and ovarian cancers.</span> 173 2 103 104 10.1001/jamainternmed.2013.2729 http://archinte.jamanetwork.com/article.aspx?articleID=1483960